Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen
- 15 April 2004
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (10) , 1067-1068
- https://doi.org/10.1038/sj.bmt.1704492
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: Cost, safety, and long-term efficacyAnnals of Oncology, 1997
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patientsBlood, 1993
- The usefulness of analysis of survival by tumor response.Journal of Clinical Oncology, 1986
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986